Komatsu Ryuichi | Safety Assessment Department Chugai Pharmaceutical Co. Ltd.
スポンサーリンク
概要
関連著者
-
KOMATSU Ryuichi
Safety Assessment Department, Chugai Pharmaceutical Co., Ltd.
-
HONDA Masaki
Safety Assessment Department, Chugai Pharmaceutical Co., Ltd.
-
KIMURA Kazuya
Safety Assessment Department, Chugai Pharmaceutical Co., Ltd.
-
Tabo Mitsuyasu
Safety Assessment Department Chugai Pharmaceutical Co. Ltd.
-
Tabo Mitsuyasu
Safety Assessment Department Chugai Pharmaceutical Co. Ltd.:laboratory Of Pharmacology Graduate Scho
-
Kimura Kazuya
Japan Pharmaceutical Manufacturers Assoc. Drug Evaluation Committee Non-clinical Evaluation Subcommi
-
Kimura Kazuya
Fuji Gotemba Research Laboratories Chugai Pharmaceutical Co. Ltd.
-
Tabo Mitsuyasu
Fuji Gotemba Research Laboratories Chugai Pharmaceutical Co. Ltd.
-
Komatsu Ryuichi
Safety Assessment Department Chugai Pharmaceutical Co. Ltd.
-
Honda Masaki
Safety Assessment Department Chugai Pharmaceutical Co. Ltd.
-
TABO Mitsuyasu
Safety Assessment Department, Chugai Pharmaceutical Co., Ltd.
-
ISOBE Takehito
Safety Assessment Department, Chugai Pharmaceutical Co., Ltd.
-
YAMADA Yuichiro
Safety Assessment Department, Chugai Pharmaceutical Co., Ltd.
-
Isobe Takehito
Safety Assessment Department Chugai Pharmaceutical Co. Ltd.
-
Kimura Kazuya
Safety Assessment Dep. Chugai Pharmaceutical Co. Ltd.
-
Tabo Mitsuyasu
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd.
-
Komatsu Ryuichi
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd.
-
Honda Masaki
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd.
-
Itoh Misae
Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd.
-
Tabo Mitsuyasu
Safety Assessment Dep. Chugai Pharmaceutical Co. Ltd.
-
Yamada Yuichiro
Safety Assessment Department Chugai Pharmaceutical Co. Ltd.
-
Itoh Misae
Fuji Gotemba Research Laboratories Chugai Pharmaceutical Co. Ltd.
-
Honda Masaki
Safety Assessment Dep. Chugai Pharmaceutical Co. Ltd. Jpn
著作論文
- Accurate detection of drug-induced delayed ventricular repolarization with a suitable correction formula in Langendorff guinea pig heart
- Cardiovascular safety profile of MA-2029, a novel motilin receptor antagonist